![]() |
시장보고서
상품코드
1473723
High Throughput Screening 시장 예측(-2030년)High Throughput Screening Market Research Report Market Forecast till 2030 |
High Throughput Screening 시장 규모는 예측 기간 중 9.70%의 CAGR로 성장할 것으로 예측되고 있습니다.
시장 성장의 요인으로서는 게놈 연구의 발전, 맞춤형 의료에 대한 관심의 증가, 연구개발 투자의 증가, 인지도의 향상과 채택의 증가를 들 수 있습니다.
High Throughput Screening 시장은 맞춤형 의료에 대한 관심의 증가에 의해 대폭적인 성장을 달성하고 있습니다. 대량의 DNA 및 RNA 염기 배열을 신속하고 비용 효율적으로 결정할 수 있는 High Throughput Screening은 맞춤형 의료의 진보에서 매우 중요한 역할을 담당하고 있습니다.
지역별 인사이트
2022년의 시장 점유율에서는 북미 지역이 42.96%로 최대 규모를 보이며, 예측 기간 중 CAGR에서는 아시아태평양이 11.01%로 최대 성장을 보일 전망입니다. 이 시장의 성장은 세계에서의 임상시험 수의 증가 및 R&D의 확대에 의해 추진되고 있습니다.
유럽의 High Throughput Screening 시장의 성장은 신약 리드 분자의 발견을 가속하기 위한 HTS 프로젝트의 추진에 의해 초래되고 있습니다.
세계의 High Throughput Screening 시장을 조사했으며, 시장의 정의와 개요, 시장 성장에 대한 영향요인 및 시장 기회의 분석, 시장 규모의 추이·예측, 각종 구분·지역별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.
High Throughput Screening Market is anticipated to register a significant CAGR of 9.70% during the forecast period.
The variables adding to the development of the market are the developing genomic research exercises, rising interest for customized medication, expanding interest in innovative work, and expanding mindfulness and reception.
The high-throughput screening market is encountering significant development because of the rising interest for customized medication. Customized medication, otherwise called accuracy medication, is an inventive methodology that thinks about a singular's exceptional hereditary cosmetics, way of life, and natural variables to tailor clinical medicines and mediations. High-throughput screening, with its capacity to succession enormous volumes of DNA or RNA quickly and cost-really, assumes a crucial part in the headway of customized medication. One of the essential drivers behind the rising interest for customized medication is the developing acknowledgment that people answer diversely to medicines because of their one-of-a-kind hereditary variety. High-throughput screening empowers the ID of sickness related hereditary variations and offers bits of knowledge into the hereditary variables fundamental the viability and security of explicit treatments. By breaking down a person's hereditary data, medical care experts can decide the most appropriate therapy choices and upgrade measurements, bringing about superior patient results.
Market Segment Insights
Based on product & service, the High Throughput Screening Market has been segmented into consumables, instruments, and software & services. Based on technology, the Market has classified into cell-based assays, Lab-on-a-Chip (LOC), ultra-high-throughput screening, label-free technology, and others.
Based on application, the High Throughput Screening Market has segmented into drug discovery, biochemical screening, cell & organ-based screening, and others. In terms of end user, the Market has categorized into pharmaceutical and biotechnology companies, research institutes and organizations, and contract research organizations.
Regional Insights
North America represented the biggest market portion of 42.96% in 2022 and Asia-Pacific is projected to develop at the highest CAGR of 11.01% during the figure time frame. Moreover, market development is driven by expanding clinical preliminary numbers across the globe, and developing exploration and improvement. In addition, the underneath diagram addresses the quantity of clinical preliminaries for every region began in 2022. The market development has been driven by inorganic procedures to extend high-throughput screening (HTS) answers for measure biochemical exercises and recognize restricting associations, which speed up the timetable and lessen expenses to distinguish lead drug competitors. For example, in January 2023, Charles Waterway Research Facilities Global, Inc. (US) procured SAMDI Tech, Inc. (US), a main supplier of HTS answers for grow HTS portfolio.
The development of the European high-throughput screening market is driven by elevating HTS undertakings to speed up the revelation of a lead particle for another medication. For example, in Walk 2023, SCREENTECH opened under the correlative arrangement for biotechnology in Catalonia (Spain). This drive focused on the advancement of new ventures in view of the medication screening and medication target connection examination stage at IRB Barcelona (US).
In addition, the high guilty pleasure of high-throughput screening fire up designers like CN Bio (UK), Evosep (Denmark), Ovizio (Belgium), and Oxford Nanopore Advancements plc. (UK) through raising financing and consolidating advancement is setting out enormous open doors for the region's development.
Key Companies in the High Throughput Screening Market are Agilent Technologies Inc, Merck KGaA, Corning Incorporated, Tecan Trading AG, PerkinElmer Inc, Luminex Corporation, Beckman Coulter Inc, Hoffmann-La Roche Ltd, Promega Corporation, Hamilton Company, and Others.